NFE2L2 and relapsing-remitting multiple sclerosis: For example, Dimethyl fumarate (DMF), an NRF2 activator, is the first Food and Drug Administration (FDA)-licensed KEAP1-NRF2 protein-protein interaction inhibitor and is used as an oral first-line therapy for relapsing-remitting multiple sclerosis [192].